Drug-spending increase highest in four years
The price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc. CEO David Snow said.
Pharmaceutical
Articles
Latest Lilly job cuts target marketing employees
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1
billion in annual expenses.
Lilly hopes Elanco unit becomes a cash cow
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using
Elanco’s productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge,
he has Elanco developing products to help organic farmers, too.
Lilly sues to block copy of Evista osteoporosis drug
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.’s osteoporosis medicine. Indianapolis-based
Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
Closing of Purdue’s Chao Center is setback for BioCrossroads
The university is hoping to find a private company to take over the 5-year-old facility, which formulated and manufactured
small batches of drugs used in clinical trials.
Medco Health profits climb as it adds big clients
Medco, which operates a major pharmacy and distribution center in Whitestown, got a boost from higher prices on brand-name
drugs and from greater sales of more profitable generic drugs.
Chao exit hurts drug development industry
Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow
a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for
the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.
Purdue drug maker closing its doors after 5 years
The Purdue Research Foundation says the Chao Center for Industrial Pharmacy and Contract Manufacturing was unable to become
self-sustaining in part because of the recession.
Harlan Labs names new CEO
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
Drug prices rise ahead of rebates
Drug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised
as part of the health reform law.
Lilly to pay $400M to repurchase Cymbalta rights
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European
partner Boehringer Ingelheim for an initial payment of $400 million.
Lilly diabetes drug may have cancer risk, FDA says
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Louisiana gets $20M in Lilly drug settlement
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Lilly wins court ban on generic copy of Gemzar
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Lilly drug wins U.K. backing as cancer therapy
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Lilly to let 115 workers go in new outsourcing deal
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Lilly sues Hospira over generic version of Gemzar
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
Ariad loses $65M patent appeal against Eli Lilly
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Bill kicks off years of change for local health care players
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Reform offers risk, opportunities for Lilly, WellPoint
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.